The US Food and Drug Administration has approved expanded labeling forTeva Pharmaceutical's multiple sclerosis drug Copaxone (glatiramer acetate for injection).
The new label follows a recent study which examined various magnetic resonance imaging measures of disease activity and burden of disease. The primary outcome measure was the total number of enhancing lesions, which correlate to perivascular inflammation and blood brain disruption, on images over a nine-month period. The results demonstrated that Copaxone caused a significant reduction of MRI enhanced lesions, compared to placebo, in patients with MS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze